<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021878</url>
  </required_header>
  <id_info>
    <org_study_id>PUCPR 01</org_study_id>
    <nct_id>NCT01021878</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients</brief_title>
  <acronym>STARCH</acronym>
  <official_title>A Study to Evaluate the Effects of Icodextrin vs 2.5% Dianeal Used for the Long Dwell in Apd: a Randomized, Open-label Clinical Trial to Analyse the Insulin Resistance Using the Homa Index in Prevalent, Non-diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontifícia Universidade Católica do Paraná</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. LOCATION OF STUDY: Multicentric study in Brazil.

        2. PURPOSE OF THE STUDY: To measure changes in HOMA index when non-diabetic patients in APD
           were exposed to 7,5% Icodextrin for the long-dwell; and to compare such changes with
           those produced by 2,5% glucose for the long-dwell.

        3. PRIMARY OUTCOME: The primary efficacy outcome was to measure HOMA index to set the
           differences with regard to baseline values of this variable for the two groups as well
           as in each group, which showed control of the glucose metabolism.

      STAGE OF THE STUDY : Phase IV postmarket study

      DESIGN: Randomized, open-label, multicenter study. Patients were randomized to receive either
      to Extraneal (7,5% Icodextrin) or 2.5% Dianeal during the long-dwell.

      SAMPLE SIZE: Randomization Upon completion of the study TOTAL: 120 60 ExtranealTM 60 30
      Dianeal® 60 30

      Duration: 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. SUMMARY OF THE STUDY

      1.1 PROTOCOLE TITLE : A RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE EFFECTS OF
      ICODEXTRIN Vs 2,5% DIANEAL USED FOR THE LONG-DWELL ON HOMA INDEX IN PREVALENT, NON-DIABETIC,
      PATIENTS IN AUTOMATED PERITONEAL DIALYSIS (APD)

      1.2 MAIN RESEARCHERS: Roberto Pecoits Filho, Thyago P. Moraes

      1.3 LOCATION OF STUDY: Multicentric study in Brazil.

      1.4 PURPOSE OF THE STUDY: To measure changes in HOMA index when non-diabetic patients in APD
      were exposed to 7,5% Icodextrin for the long-dwell; and to compare such changes with those
      produced by 2,5% glucose for the long-dwell.

      1.5 PRIMARY OUTCOME: The primary efficacy outcome was to measure HOMA index to set the
      differences with regard to baseline values of this variable for the two groups as well as in
      each group, which showed control of the glucose metabolism.

      1.6 SECONDARY OUTCOMES:

      1.6.1 Other efficacy outcomes were total UF, long-dwell UF, and preprandial glycemia (taken
      first in the morning before breakfast), serum insulin levels and glycated haemoglobin.

      1.6.2 The incidence of adverse events will be measured as a safety outcome.

      1.7 STAGE OF THE STUDY : Phase IV postmarket study

      1.8 DESIGN: Randomized, open-label, multicenter study. Patients were randomized to receive
      either to Extraneal (7,5% Icodextrin) or 2.5% Dianeal during the long-dwell.

      1.9 SAMPLE SIZE: Randomization Upon completion of the study TOTAL: 100 60 ExtranealTM 50 30
      Dianeal® 50 30

      1.12 PHARMACEUTICAL FORM, ROUTE OF DE ADMINISTRATION AND DOSAGE

      ExtranealTM (7.5% Icodextrin) solution for Peritoneal Dialysis:

      It is labelled as &quot;solution for dialysis&quot; to be administered within the study for a period of
      one (1) year.

      Available in 2 liter bags of peritoneal dialysis solution (Twin Bag) for CAPD, this product
      will be used during the long-dwell.

      Dianeal® PD4 (2.5% Dextrose) solution for Peritoneal Dialysis:

      It is labelled as 2.27% glucose-based &quot;solution for dialysis&quot;, to be administered within the
      study for a period of one (1) year.

      Available in 2 and 2.5 liter bags of peritoneal dialysis solution (Twin Bag) for CAPD, this
      product will be used during the long-dwell.

      Duration: 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor</measure>
    <time_frame>3 months</time_frame>
    <description>Adjusted HOMA index score at 3 months using baseline values as a covariate and groups as the fixed factor. HOMA index was calculated as follows:
(fasting glucose(mg/dl) x fasting serum insulin (μU/mL))/405</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral Fasting Serum Glucose</measure>
    <time_frame>3 months</time_frame>
    <description>Serum glucose measured in oral fasting but not peritoneal fasting.
For this outcome we compared groups using analysis of covariance (ANCOVA) using the baseline values as covariate, groups as the fixed factor and the value obtained at 90 days as the dependent variable. Significance level for alpha was setting at &lt; 0.05.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>3 months</time_frame>
    <description>Serum insulin was log-transformed to meet all criteria for ANCOVA. The baseline value was treated as covariate, groups as the fixed factor and the serum insulin at 3 months as the dependent variable. Serum insulin was measured in oral fasting by chemioluminescense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Hemoglobin</measure>
    <time_frame>3 months</time_frame>
    <description>Adjusted glycated hemoglobin was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of HbA1c was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.
Glycated hemoglobin was measured by high-performance liquid chromatography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ultrafiltration</measure>
    <time_frame>3 months</time_frame>
    <description>Total ultrafiltration obtained in 24 hours was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of total ultrafiltration was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Disorders Associated With Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>icodextrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glucose sparing alternative dialysis solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dextrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dianeal, Control group, standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>icodextrin</intervention_name>
    <description>glucose sparing dialysis solution</description>
    <arm_group_label>icodextrin</arm_group_label>
    <other_name>Extraneal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dianeal</intervention_name>
    <description>glucose based dialysis solution</description>
    <arm_group_label>dextrose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.10.1 Older than 18 years old.

          -  High PET value, average-high or average-low.

          -  Cause of renal chronic disease other than diabetes mellitus.

          -  Patient in APD

          -  Prevalent patient in APD (defined as at least 90 total days of dialysis therapy)

        Exclusion Criteria:

          -  Not willing to participate.

          -  A Charlson comorbidity index &gt;7, or a life expectancy &lt; 12 months as assessed by the
             treating physician.

          -  Positive VIH.

          -  Episodes of peritonitis during the month preceding the randomization.

          -  Significant cardiovascular, metabolic or infectious complications during the month
             preceding the randomization.

          -  Patients with active cancer.

          -  Patients with known allergies to corn starch polymers.

          -  Patients who are unable to provide an informed consent because of significant
             psychiatric disorder or mental illness

          -  Patients not meeting adequacy goals several months after the change in the dosage
             regime.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Pecoits-Filho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidade Catolica do Parana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital São João de Deus</name>
      <address>
        <city>Divinópolis</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Uberlândia</name>
      <address>
        <city>Uberlândia</city>
        <state>Minas Gerais</state>
        <zip>38400 089</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Rim de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Doencas Renais</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80220901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nefroclinica de Caxias do Sul</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande do Sul</state>
        <zip>95010-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual Paulista</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinese</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <zip>49075210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023 062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2009</study_first_submitted>
  <study_first_submitted_qc>November 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <results_first_submitted>June 24, 2014</results_first_submitted>
  <results_first_submitted_qc>September 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2014</results_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontifícia Universidade Católica do Paraná</investigator_affiliation>
    <investigator_full_name>Roberto Pecoits-Filho</investigator_full_name>
    <investigator_title>MD, PhD, FASN</investigator_title>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Renal replacement therapy</keyword>
  <keyword>Dialysis solutions</keyword>
  <keyword>Icodextrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Icodextrin</title>
          <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution
N=33</description>
        </group>
        <group group_id="P2">
          <title>Dextrose</title>
          <description>Control group, standard treatment
Dianeal: glucose based dialysis solution
N=27</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>From October 2009 to February 2012 60 patients were randomly assigned to the intervention (n=33) or the control (n=27) group. Completed follow-up was achieved for 34 patients, of which 17 of the control and 17 of the study group.</population>
      <group_list>
        <group group_id="B1">
          <title>Icodextrin</title>
          <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution</description>
        </group>
        <group group_id="B2">
          <title>Dextrose</title>
          <description>Control group, standard treatment
Dianeal: glucose based dialysis solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="15.5"/>
                    <measurement group_id="B2" value="54.1" spread="17.4"/>
                    <measurement group_id="B3" value="52.1" spread="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA index</title>
          <units>IR score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.10" spread="1.10"/>
                    <measurement group_id="B2" value="1.77" spread="1.00"/>
                    <measurement group_id="B3" value="1.95" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor</title>
        <description>Adjusted HOMA index score at 3 months using baseline values as a covariate and groups as the fixed factor. HOMA index was calculated as follows:
(fasting glucose(mg/dl) x fasting serum insulin (μU/mL))/405</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icodextrin</title>
            <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution</description>
          </group>
          <group group_id="O2">
            <title>Dextrose</title>
            <description>Control group, standard treatment
Dianeal: glucose based dialysis solution</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor</title>
          <description>Adjusted HOMA index score at 3 months using baseline values as a covariate and groups as the fixed factor. HOMA index was calculated as follows:
(fasting glucose(mg/dl) x fasting serum insulin (μU/mL))/405</description>
          <units>IR score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.23" upper_limit="1.74"/>
                    <measurement group_id="O2" value="1.89" lower_limit="1.62" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Fasting Serum Glucose</title>
        <description>Serum glucose measured in oral fasting but not peritoneal fasting.
For this outcome we compared groups using analysis of covariance (ANCOVA) using the baseline values as covariate, groups as the fixed factor and the value obtained at 90 days as the dependent variable. Significance level for alpha was setting at &lt; 0.05.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icodextrin</title>
            <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution</description>
          </group>
          <group group_id="O2">
            <title>Dextrose</title>
            <description>Control group, standard treatment
Dianeal: glucose based dialysis solution</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Fasting Serum Glucose</title>
          <description>Serum glucose measured in oral fasting but not peritoneal fasting.
For this outcome we compared groups using analysis of covariance (ANCOVA) using the baseline values as covariate, groups as the fixed factor and the value obtained at 90 days as the dependent variable. Significance level for alpha was setting at &lt; 0.05.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="20.0" lower_limit="87.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="94.5" spread="17.9" lower_limit="88.7" upper_limit="100.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Insulin</title>
        <description>Serum insulin was log-transformed to meet all criteria for ANCOVA. The baseline value was treated as covariate, groups as the fixed factor and the serum insulin at 3 months as the dependent variable. Serum insulin was measured in oral fasting by chemioluminescense.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icodextrin</title>
            <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution
There were a total of 25 adverse events reported of which 10 in the control group and 15 in the intervention group. Six were considered a severe event, 4 in the control group and 2 in the intervention group.</description>
          </group>
          <group group_id="O2">
            <title>Dextrose</title>
            <description>Control group, standard treatment
Dianeal: glucose based dialysis solution
There were a total of 25 adverse events reported of which 10 in the control group and 15 in the intervention group. Six were considered a severe event, 4 in the control group and 2 in the intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin</title>
          <description>Serum insulin was log-transformed to meet all criteria for ANCOVA. The baseline value was treated as covariate, groups as the fixed factor and the serum insulin at 3 months as the dependent variable. Serum insulin was measured in oral fasting by chemioluminescense.</description>
          <units>log(mmol/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.70" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.81" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Hemoglobin</title>
        <description>Adjusted glycated hemoglobin was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of HbA1c was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.
Glycated hemoglobin was measured by high-performance liquid chromatography.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icodextrin</title>
            <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution</description>
          </group>
          <group group_id="O2">
            <title>Dextrose</title>
            <description>dianeal, Control group, standard treatment
Dianeal: glucose based dialysis solution</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Hemoglobin</title>
          <description>Adjusted glycated hemoglobin was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of HbA1c was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.
Glycated hemoglobin was measured by high-performance liquid chromatography.</description>
          <units>percentage of haemoglobin</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="4.73" upper_limit="5.21"/>
                    <measurement group_id="O2" value="4.86" lower_limit="4.62" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Ultrafiltration</title>
        <description>Total ultrafiltration obtained in 24 hours was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of total ultrafiltration was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Icodextrin</title>
            <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution</description>
          </group>
          <group group_id="O2">
            <title>Dextrose</title>
            <description>dianeal, Control group, standard treatment
Dianeal: glucose based dialysis solution</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ultrafiltration</title>
          <description>Total ultrafiltration obtained in 24 hours was obtained and compared between groups using analysis of covariance (ANCOVA). The baseline values of total ultrafiltration was used as covariate, the groups as the fixed factor and the value obtained at 90 days as the dependent variable.</description>
          <units>millilitre</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="958" lower_limit="818" upper_limit="1097"/>
                    <measurement group_id="O2" value="656" lower_limit="517" upper_limit="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Patients were trained to report adverse effects immediately. Otherwise, adverse effects were checked every other week.</desc>
      <group_list>
        <group group_id="E1">
          <title>Icodextrin</title>
          <description>glucose sparing alternative dialysis solution
icodextrin: glucose sparing dialysis solution
There were a total of 25 adverse events reported of which 10 in the control group and 15 in the intervention group. Six were considered a severe event, 4 in the control group and 2 in the intervention group.</description>
        </group>
        <group group_id="E2">
          <title>Dextrose</title>
          <description>Control group, standard treatment
Dianeal: glucose based dialysis solution
There were a total of 25 adverse events reported of which 10 in the control group and 15 in the intervention group. Six were considered a severe event, 4 in the control group and 2 in the intervention group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Sepsis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <description>Peritonitis related to Peritoneal dialysis</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exit-site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ultrafiltration Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roberto Pecoits-Filho and Dr. Thyago P. Moraes</name_or_title>
      <organization>Pontifícia Universidade Católica do Paraná</organization>
      <phone>554132713150</phone>
      <email>r.pecoits@pucpr.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

